NASDAQ:ALEC Alector Q3 2024 Earnings Results & Report $2.08 +0.06 (+2.97%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.07 -0.01 (-0.48%) As of 10/9/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alector beat analyst earnings expectations but missed on revenue in its Q3 2024 results, released November 6, 2024. The company reported EPS of -$0.43 versus the -$0.53 consensus estimate, while revenue of $15.34 million fell short of the $16.33 million estimate by $0.99 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 6, 2024TimeAfter Market ClosesConference Call4:00 PM ET Alector EPS ResultsActual EPS-$0.43Consensus EPS -$0.53Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate8 of last 8 quartersAlector Revenue ResultsActual Revenue$15.34 millionExpected Revenue$16.33 millionBeat/MissMissed by -$990.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAlector's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alector Q3 2024 Earnings FAQ Did Alector beat earnings estimates for Q3 2024? Alector (NASDAQ:ALEC) reported earnings of -$0.43 per share for Q3 2024, beating the consensus estimate of -$0.53. The report was announced on Wednesday, November 6, 2024. What was Alector's revenue for Q3 2024? Alector reported revenue of $15.34 million for Q3 2024, against a consensus estimate of $16.33 million. When is Alector's next earnings date? Alector's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alector on the company's earnings history page. Alector Earnings HeadlinesMorgan Stanley Remains a Sell on Alector (ALEC)October 8 at 6:50 PM | theglobeandmail.comAlector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineOctober 7 at 4:05 PM | globenewswire.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.October 10 at 1:00 AM | Stansberry Research (Ad)Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's DealOctober 6, 2026 | finance.yahoo.comAlector shares up after sealing $1.27bn Roche Parkinson’s disease license dealOctober 6, 2026 | finance.yahoo.comOptogenetics researchers win a Nobel Prize; Roche bets on Alector brain drugOctober 6, 2026 | finance.yahoo.comSee More Alector Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email. Email Address About AlectorAlector (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease. Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells. The program is being developed for frontotemporal dementia caused by progranulin gene mutations. The company has also pursued additional investigational programs targeting immune and neurological pathways relevant to neurodegenerative disorders. Founded in 2013, Alector is headquartered in South San Francisco, California. The company was co-founded by Arnon Rosenthal, Ph.D., who has served as its chief executive officer, and entrepreneur Tillman Gerngross, Ph.D. Alector’s research and development activities are primarily focused on advancing potential treatments for patients in the United States and other international markets through clinical development and collaborations.View Alector ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
